AU2003299065B2 - Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes - Google Patents

Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes Download PDF

Info

Publication number
AU2003299065B2
AU2003299065B2 AU2003299065A AU2003299065A AU2003299065B2 AU 2003299065 B2 AU2003299065 B2 AU 2003299065B2 AU 2003299065 A AU2003299065 A AU 2003299065A AU 2003299065 A AU2003299065 A AU 2003299065A AU 2003299065 B2 AU2003299065 B2 AU 2003299065B2
Authority
AU
Australia
Prior art keywords
pyridylmethyl
vitamin
combination
csf
phthalazine derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003299065A
Other languages
English (en)
Other versions
AU2003299065A1 (en
Inventor
Margaret Han Dugan
Alan List
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Arizona's Public Universities
Original Assignee
Novartis AG
University of Arizona
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, University of Arizona, Arizona's Public Universities filed Critical Novartis AG
Publication of AU2003299065A1 publication Critical patent/AU2003299065A1/en
Application granted granted Critical
Publication of AU2003299065B2 publication Critical patent/AU2003299065B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003299065A 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes Ceased AU2003299065B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24
US60/413,176 2002-09-24
PCT/EP2003/010578 WO2004028542A1 (en) 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Publications (2)

Publication Number Publication Date
AU2003299065A1 AU2003299065A1 (en) 2004-04-19
AU2003299065B2 true AU2003299065B2 (en) 2006-10-26

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299065A Ceased AU2003299065B2 (en) 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Country Status (22)

Country Link
US (1) US20060128716A1 (enExample)
EP (1) EP1545534B1 (enExample)
JP (1) JP2006502195A (enExample)
KR (1) KR20050074450A (enExample)
CN (1) CN100372535C (enExample)
AT (1) ATE359789T1 (enExample)
AU (1) AU2003299065B2 (enExample)
BR (1) BR0314647A (enExample)
CA (1) CA2499738A1 (enExample)
CR (1) CR7754A (enExample)
DE (1) DE60313344T2 (enExample)
EC (1) ECSP055700A (enExample)
ES (1) ES2285251T3 (enExample)
HR (1) HRP20050281A2 (enExample)
MX (1) MXPA05003161A (enExample)
NO (1) NO20051936L (enExample)
PL (1) PL374696A1 (enExample)
PT (1) PT1545534E (enExample)
RS (1) RS20050228A (enExample)
RU (1) RU2353364C2 (enExample)
WO (1) WO2004028542A1 (enExample)
ZA (1) ZA200502212B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1391206B1 (en) * 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
US7915410B2 (en) 2005-09-09 2011-03-29 Bristol-Myers Squibb Company Acyclic IKur inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
RU2136308C1 (ru) * 1994-11-16 1999-09-10 Жемчугов Владислав Евгеньевич Стимулятор роста костно-мозговых клеток человека
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ATE329596T1 (de) * 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
EP1246617B1 (en) * 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer

Also Published As

Publication number Publication date
ZA200502212B (en) 2006-02-22
DE60313344D1 (de) 2007-05-31
WO2004028542A1 (en) 2004-04-08
EP1545534A1 (en) 2005-06-29
US20060128716A1 (en) 2006-06-15
CA2499738A1 (en) 2004-04-08
RU2005112711A (ru) 2006-02-27
JP2006502195A (ja) 2006-01-19
CN100372535C (zh) 2008-03-05
ES2285251T3 (es) 2007-11-16
ECSP055700A (es) 2005-08-11
MXPA05003161A (es) 2005-09-12
PT1545534E (pt) 2007-06-22
KR20050074450A (ko) 2005-07-18
HRP20050281A2 (en) 2006-07-31
CN1684684A (zh) 2005-10-19
BR0314647A (pt) 2005-08-02
ATE359789T1 (de) 2007-05-15
RS20050228A (sr) 2007-08-03
NO20051936L (no) 2005-06-23
DE60313344T2 (de) 2008-01-03
RU2353364C2 (ru) 2009-04-27
AU2003299065A1 (en) 2004-04-19
EP1545534B1 (en) 2007-04-18
CR7754A (es) 2005-12-02
PL374696A1 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
EP1339458B1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
NZ550174A (en) Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof
KR20220124739A (ko) 암의 치료를 위한 병용 요법
MXPA04006822A (es) Combinaciones que comprenden epotilonas y anti-metabolitos.
EP1545534B1 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
US20090233939A1 (en) Treatment of amm
AU2006271650B2 (en) Combination of a pyrimidylaminobenzamide and an MTOR kinase inhibitor
AU2008203233B2 (en) Combinations comprising epothilones and pharmaceutical uses thereof
KR20240056487A (ko) 고형 종양을 치료하기 위한 약제학적 조성물
JP2006502195A5 (enExample)
US20090239872A1 (en) Treatment of mesothelioma
US20060252763A1 (en) Treatment of von hippel lindau disease
ZA200306404B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired